Edwards Lifesciences Corporation (NYSE:EW) Short Interest Update

Key Points

• Short interest in Edwards Lifesciences Corporation increased by 27.1% in August, reaching a total of 10,350,000 shares, which represents 1.8% of the company's total shares.
• Insiders sold substantial amounts of stock recently, with Larry L. Wood selling 8,950 shares and Daniel J. Lippis selling 4,114 shares, resulting in decreases of 4.15% and 15.75% in their respective positions.
• Analysts have issued an average rating of "Moderate Buy" for Edwards Lifesciences, with a consensus price target set at $86.26.

Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) was the target of a significant growth in short interest in the month of August. As of August 31st, there was short interest totaling 10,350,000 shares, a growth of 27.1% from the August 15th total of 8,140,000 shares. Based on an average trading volume of 4,080,000 shares, the days-to-cover ratio is presently 2.5 days. Approximately 1.8% of the company's shares are sold short. Approximately 1.8% of the company's shares are sold short. Based on an average trading volume of 4,080,000 shares, the days-to-cover ratio is presently 2.5 days.

Edwards Lifesciences Stock Performance

Shares of EW traded down $0.16 during mid-day trading on Friday, hitting $74.39. The company's stock had a trading volume of 8,177,895 shares, compared to its average volume of 3,799,900. Edwards Lifesciences has a one year low of $64.00 and a one year high of $83.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The firm has a market capitalization of $43.67 billion, a PE ratio of 10.70, a price-to-earnings-growth ratio of 3.60 and a beta of 1.07. The stock's 50-day moving average is $78.76 and its two-hundred day moving average is $75.49.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the prior year, the firm earned $0.70 EPS. The business's revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences will post 2.45 EPS for the current year.

Insider Buying and Selling

In other news, insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. This represents a 15.75% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is owned by insiders.

Institutional Trading of Edwards Lifesciences

Several institutional investors have recently modified their holdings of the company. Brighton Jones LLC acquired a new stake in Edwards Lifesciences during the fourth quarter worth $266,000. Bank Pictet & Cie Europe AG increased its stake in Edwards Lifesciences by 16.7% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 10,231 shares of the medical research company's stock valued at $757,000 after acquiring an additional 1,463 shares during the period. Snowden Capital Advisors LLC bought a new stake in Edwards Lifesciences in the fourth quarter valued at about $204,000. State of Wyoming raised its position in Edwards Lifesciences by 128.2% in the fourth quarter. State of Wyoming now owns 1,935 shares of the medical research company's stock worth $143,000 after purchasing an additional 1,087 shares in the last quarter. Finally, Tidal Investments LLC boosted its holdings in Edwards Lifesciences by 18.8% during the fourth quarter. Tidal Investments LLC now owns 46,970 shares of the medical research company's stock valued at $3,477,000 after purchasing an additional 7,438 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. JPMorgan Chase & Co. upped their price objective on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the company a "neutral" rating in a research note on Friday, July 25th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the company a "buy" rating in a research note on Friday, July 25th. Evercore ISI upped their price objective on shares of Edwards Lifesciences from $77.00 to $80.00 and gave the company an "in-line" rating in a research note on Friday, July 25th. Morgan Stanley upped their price objective on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company an "equal weight" rating in a research note on Tuesday, July 15th. Finally, Mizuho upped their price objective on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the company an "outperform" rating in a research note on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has an average rating of "Moderate Buy" and an average price target of $87.17.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.